Intrathecal methotrexate affects cognitive function in children with medulloblastoma

Daria Riva, C. Giorgi, F. Nichelli, S. Bulgheroni, M. Massimino, G. Cefalo, L. Gandola, M. Giannotta, I. Bagnasco, V. Saletti, C. Pantaleoni

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Cognitive impairment occurs after malignant brain tumor treatment in children, following brain radiotherapy and systemic and intrathecal chemotherapy. Objectives: 1) To compare two groups of children who underwent surgery for cerebellar medulloblastoma with their cousins and siblings, assessing intelligence, executive function, attention, visual perception, and short-term memory. Both groups were treated with the same combined radiotherapy-chemotherapy, but differed in that only one group received intrathecal methotrexate (MTX+). 2) To relate these measures to MRI findings (leukomalacia). Results: The two groups performed worse than their control subjects in all tests. The MTX+ group younger than 10 years performed significantly worse in all tests, particularly executive ones. The group older than 10 years performed significantly worse only in short-term memory. Younger patients without MTX performed significantly worse than controls only in some neuropsychological measures; there were no differences between older patients and control subjects. Only in the MTX+ group was there a direct correlation between extent of leukomalacia and performance in some tests. Conclusions: The administration of intrathecal methotrexate to children with medulloblastoma worsens the cognitive deficits induced by chemotherapy and radiotherapy. The use of intrathecal methotrexate in the treatment of medulloblastoma and other malignancies should be reassessed.

Original languageEnglish
Pages (from-to)48-53
Number of pages6
JournalNeurology
Volume59
Issue number1
Publication statusPublished - Jul 9 2002

Fingerprint

Medulloblastoma
Methotrexate
Cognition
Radiotherapy
Short-Term Memory
Drug Therapy
Visual Perception
Executive Function
Intelligence
Brain Neoplasms
Siblings
Brain
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Intrathecal methotrexate affects cognitive function in children with medulloblastoma. / Riva, Daria; Giorgi, C.; Nichelli, F.; Bulgheroni, S.; Massimino, M.; Cefalo, G.; Gandola, L.; Giannotta, M.; Bagnasco, I.; Saletti, V.; Pantaleoni, C.

In: Neurology, Vol. 59, No. 1, 09.07.2002, p. 48-53.

Research output: Contribution to journalArticle

@article{3792efc2fb8e4b6c9039c18c17619adf,
title = "Intrathecal methotrexate affects cognitive function in children with medulloblastoma",
abstract = "Background: Cognitive impairment occurs after malignant brain tumor treatment in children, following brain radiotherapy and systemic and intrathecal chemotherapy. Objectives: 1) To compare two groups of children who underwent surgery for cerebellar medulloblastoma with their cousins and siblings, assessing intelligence, executive function, attention, visual perception, and short-term memory. Both groups were treated with the same combined radiotherapy-chemotherapy, but differed in that only one group received intrathecal methotrexate (MTX+). 2) To relate these measures to MRI findings (leukomalacia). Results: The two groups performed worse than their control subjects in all tests. The MTX+ group younger than 10 years performed significantly worse in all tests, particularly executive ones. The group older than 10 years performed significantly worse only in short-term memory. Younger patients without MTX performed significantly worse than controls only in some neuropsychological measures; there were no differences between older patients and control subjects. Only in the MTX+ group was there a direct correlation between extent of leukomalacia and performance in some tests. Conclusions: The administration of intrathecal methotrexate to children with medulloblastoma worsens the cognitive deficits induced by chemotherapy and radiotherapy. The use of intrathecal methotrexate in the treatment of medulloblastoma and other malignancies should be reassessed.",
author = "Daria Riva and C. Giorgi and F. Nichelli and S. Bulgheroni and M. Massimino and G. Cefalo and L. Gandola and M. Giannotta and I. Bagnasco and V. Saletti and C. Pantaleoni",
year = "2002",
month = "7",
day = "9",
language = "English",
volume = "59",
pages = "48--53",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Intrathecal methotrexate affects cognitive function in children with medulloblastoma

AU - Riva, Daria

AU - Giorgi, C.

AU - Nichelli, F.

AU - Bulgheroni, S.

AU - Massimino, M.

AU - Cefalo, G.

AU - Gandola, L.

AU - Giannotta, M.

AU - Bagnasco, I.

AU - Saletti, V.

AU - Pantaleoni, C.

PY - 2002/7/9

Y1 - 2002/7/9

N2 - Background: Cognitive impairment occurs after malignant brain tumor treatment in children, following brain radiotherapy and systemic and intrathecal chemotherapy. Objectives: 1) To compare two groups of children who underwent surgery for cerebellar medulloblastoma with their cousins and siblings, assessing intelligence, executive function, attention, visual perception, and short-term memory. Both groups were treated with the same combined radiotherapy-chemotherapy, but differed in that only one group received intrathecal methotrexate (MTX+). 2) To relate these measures to MRI findings (leukomalacia). Results: The two groups performed worse than their control subjects in all tests. The MTX+ group younger than 10 years performed significantly worse in all tests, particularly executive ones. The group older than 10 years performed significantly worse only in short-term memory. Younger patients without MTX performed significantly worse than controls only in some neuropsychological measures; there were no differences between older patients and control subjects. Only in the MTX+ group was there a direct correlation between extent of leukomalacia and performance in some tests. Conclusions: The administration of intrathecal methotrexate to children with medulloblastoma worsens the cognitive deficits induced by chemotherapy and radiotherapy. The use of intrathecal methotrexate in the treatment of medulloblastoma and other malignancies should be reassessed.

AB - Background: Cognitive impairment occurs after malignant brain tumor treatment in children, following brain radiotherapy and systemic and intrathecal chemotherapy. Objectives: 1) To compare two groups of children who underwent surgery for cerebellar medulloblastoma with their cousins and siblings, assessing intelligence, executive function, attention, visual perception, and short-term memory. Both groups were treated with the same combined radiotherapy-chemotherapy, but differed in that only one group received intrathecal methotrexate (MTX+). 2) To relate these measures to MRI findings (leukomalacia). Results: The two groups performed worse than their control subjects in all tests. The MTX+ group younger than 10 years performed significantly worse in all tests, particularly executive ones. The group older than 10 years performed significantly worse only in short-term memory. Younger patients without MTX performed significantly worse than controls only in some neuropsychological measures; there were no differences between older patients and control subjects. Only in the MTX+ group was there a direct correlation between extent of leukomalacia and performance in some tests. Conclusions: The administration of intrathecal methotrexate to children with medulloblastoma worsens the cognitive deficits induced by chemotherapy and radiotherapy. The use of intrathecal methotrexate in the treatment of medulloblastoma and other malignancies should be reassessed.

UR - http://www.scopus.com/inward/record.url?scp=0037047007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037047007&partnerID=8YFLogxK

M3 - Article

C2 - 12105306

AN - SCOPUS:0037047007

VL - 59

SP - 48

EP - 53

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 1

ER -